151 related articles for article (PubMed ID: 35504951)
1. RDIVpSGP motif of ASPP2 binds to 14-3-3 and enhances ASPP2/k18/14-3-3 ternary complex formulation to promote BRAF/MEK/ERK signal inhibited cell proliferation in hepatocellular carcinoma.
Yang T; Zhu C; Shi Y; Shen Y; Gao Y; Zhang B; Jin R; Liu D; Ouyang Y; Liu X; Wang W; Yang P; Xu Q; Cai J; Chen D
Cancer Gene Ther; 2022 Nov; 29(11):1616-1627. PubMed ID: 35504951
[TBL] [Abstract][Full Text] [Related]
2. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.
Yang T; Gao Y; Liu D; Wang Y; Wu J; Liu X; Shi Y; Chen D
Biochem Biophys Res Commun; 2019 Jan; 508(3):769-774. PubMed ID: 30528232
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
[TBL] [Abstract][Full Text] [Related]
4. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence.
Wang Z; Liu Y; Takahashi M; Van Hook K; Kampa-Schittenhelm KM; Sheppard BC; Sears RC; Stork PJ; Lopez CD
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):312-7. PubMed ID: 23248303
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation.
Chen R; Wang H; Liang B; Liu G; Tang M; Jia R; Fan X; Jing W; Zhou X; Wang H; Yang Y; Wei H; Li B; Zhao J
Cell Death Dis; 2016 Dec; 7(12):e2512. PubMed ID: 27929538
[TBL] [Abstract][Full Text] [Related]
6. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
7. Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma.
Liu K; Jiang T; Ouyang Y; Shi Y; Zang Y; Li N; Lu S; Chen D
Oncotarget; 2015 Jun; 6(18):16507-16. PubMed ID: 25980493
[TBL] [Abstract][Full Text] [Related]
8. ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma.
Liang B; Chen R; Song S; Wang H; Sun G; Yang H; Jing W; Zhou X; Fu Z; Huang G; Zhao J
Cell Death Dis; 2019 Nov; 10(11):830. PubMed ID: 31685796
[TBL] [Abstract][Full Text] [Related]
9. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
[TBL] [Abstract][Full Text] [Related]
10. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
11. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
12. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-ι/GLI1 pathway.
Tian L; Deng Z; Xu L; Yang T; Yao W; Ji L; Lu Y; Zhang J; Liu Y; Wang J
Cell Death Dis; 2018 Nov; 9(11):1115. PubMed ID: 30389910
[TBL] [Abstract][Full Text] [Related]
14. NEIL3 promotes hepatoma epithelial-mesenchymal transition by activating the BRAF/MEK/ERK/TWIST signaling pathway.
Lai HH; Hung LY; Yen CJ; Hung HC; Chen RY; Ku YC; Lo HT; Tsai HW; Lee YP; Yang TH; Chen YY; Huang YS; Huang W
J Pathol; 2022 Dec; 258(4):339-352. PubMed ID: 36181299
[TBL] [Abstract][Full Text] [Related]
15. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
17. Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
Wu T; Song H; Xie D; Zhao B; Xu H; Wu C; Hua K; Deng Y; Ji C; Hu J; Fang L
Int J Oncol; 2018 Jun; 52(6):2001-2010. PubMed ID: 29568874
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma.
Zhao J; Wu G; Bu F; Lu B; Liang A; Cao L; Tong X; Lu X; Wu M; Guo Y
Hepatology; 2010 Jan; 51(1):142-53. PubMed ID: 20034025
[TBL] [Abstract][Full Text] [Related]
19. ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival.
Van Hook K; Wang Z; Chen D; Nold C; Zhu Z; Anur P; Lee HJ; Yu Z; Sheppard B; Dai MS; Sears R; Spellman P; Lopez CD
Biochem Biophys Res Commun; 2017 Jan; 482(4):1271-1277. PubMed ID: 27939881
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
